Innovent throws its hat further into China's GLP-1 ring

Innovent Biologics is planning a second filing for its dual GLP-1/glucagon agonist mazdutide in China, as it tries to carve out a share of a market currently dominated by Novo Nordisk and E

Xeris’ severe low blood sugar pen gets FDA approval